- Trials with a EudraCT protocol (341)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
341 result(s) found for: Viruses.
Displaying page 8 of 18.
EudraCT Number: 2020-002713-17 | Sponsor Protocol Number: GA42469 | Start Date*: 2020-07-13 | ||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA | ||||||||||||||||||
Medical condition: Severe coronavirus disease 2019 (COVID-19) pneumonia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003978-27 | Sponsor Protocol Number: GS-US-337-1119 | Start Date*: 2014-02-20 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Ge... | |||||||||||||
Medical condition: Chronic Genotype 4 and Genotype 5 Hepatitis C Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022092-65 | Sponsor Protocol Number: ACH625-003 | Start Date*: 2011-10-13 | ||||||||||||||||
Sponsor Name:Achillion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb... | ||||||||||||||||||
Medical condition: Hepatitis C Virus Genotype 1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003339-24 | Sponsor Protocol Number: DEN-308 | Start Date*: 2022-12-21 | |||||||||||
Sponsor Name:Takeda Vaccines, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscu... | |||||||||||||
Medical condition: Dengue fever | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004541-33 | Sponsor Protocol Number: immvzmpr1 | Start Date*: Information not available in EudraCT |
Sponsor Name:Västra Götalandsregionen | ||
Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. | ||
Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002828-33 | Sponsor Protocol Number: ICRC-ICIT-01 | Start Date*: 2012-10-10 |
Sponsor Name:Fakultní nemocnice u sv. Anny v Brně | ||
Full Title: RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATH... | ||
Medical condition: Patients with endomyocardial biopsy (EMB) proven inflammatory cardiomyopathy (ICM) defined by EMB established presence of myocardial inflammation and absence of cardiotropic infectious agents estab... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000820-83 | Sponsor Protocol Number: NNL-2017 | Start Date*: 2017-07-03 | ||||||||||||||||
Sponsor Name:University of Oulu | ||||||||||||||||||
Full Title: Otitis Media and Nasopharyngeal Microbiome in Children. The change of nasopharyngeal microbiome and its role as a risk factor of otitis media. Streptococcus salivarius K12 and the change of nasop... | ||||||||||||||||||
Medical condition: We investigate role of microbiota as the risk factor of acute otitis media in children. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2024-000341-27 | Sponsor Protocol Number: DEN-324 | Start Date*: 2024-12-13 | |||||||||||
Sponsor Name:Takeda | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled (Participants aged 18 to 60 years) and Open-Label (Participants aged 4 to 17 years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 do... | |||||||||||||
Medical condition: Dengue fever | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001396-40 | Sponsor Protocol Number: R668-AD-1434 | Start Date*: 2015-10-01 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003877-23 | Sponsor Protocol Number: IMPROVE-MC | Start Date*: 2022-03-22 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-... | |||||||||||||
Medical condition: Myocarditis, inflammatory cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003350-41 | Sponsor Protocol Number: APOCT-003 | Start Date*: 2017-03-28 | |||||||||||
Sponsor Name:Division pf Paediatric and Adolescent Medicine, Oslo University Hospital | |||||||||||||
Full Title: The Diabetes Virus Detection and Intervention Trial (DiViDIntervention) | |||||||||||||
Medical condition: Newly diagnosed Type 1 Diabetes diagnosed within the previous three weeks at time of screening. Female and male patients between the ages of 6 and 15 years will be recruited. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Ongoing) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004111-37 | Sponsor Protocol Number: BHC-ABT-001 | Start Date*: 2014-10-22 | |||||||||||
Sponsor Name:BUDAI HEPATOLÓGIAI CENTRUM | |||||||||||||
Full Title: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001096-39 | Sponsor Protocol Number: MV25600 | Start Date*: 2012-07-10 | ||||||||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics | ||||||||||||||||||
Medical condition: Chronic hepatitis C | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005453-13 | Sponsor Protocol Number: EGRADICATE | Start Date*: 2016-08-03 | ||||||||||||||||
Sponsor Name:Fundació clínic per a la Recerca Biomèdica | ||||||||||||||||||
Full Title: PILOT STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF GRAZOPREVIR + ELBASVIR FOR 12 OR 16 WEEKS IN LIVER TRANSPLANT RECIPIENTS | ||||||||||||||||||
Medical condition: HCV infection and liver trasplant | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2023-000134-15 | Sponsor Protocol Number: DEN-302 | Start Date*: 2023-09-22 | |||||||||||
Sponsor Name:Takeda | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to He... | |||||||||||||
Medical condition: Dengue Fever | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000672-25 | Sponsor Protocol Number: MK-5172-059 | Start Date*: 2014-12-31 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Copr., a subsidary of Merck & Co. | |||||||||||||
Full Title: A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Chi... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) EE (Completed) PL (Completed) IT (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009214-40 | Sponsor Protocol Number: A8121014 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... | |||||||||||||
Medical condition: Treatment of chronic HCV genotype 1 infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FR (Completed) ES (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004009-15 | Sponsor Protocol Number: VIS410-203 | Start Date*: 2017-07-03 | |||||||||||
Sponsor Name:Visterra, Inc. | |||||||||||||
Full Title: Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in ... | |||||||||||||
Medical condition: Influenza A infection in hospitalized patients who need supplemental oxygen | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BG (Completed) EE (Completed) LV (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000836-27 | Sponsor Protocol Number: AI444-026 | Start Date*: 2011-09-30 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C Revised Protocol Number 05; Incorporates Ame... | |||||||||||||
Medical condition: HEPATITIS C VIRUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) ES (Completed) SE (Completed) DK (Completed) IT (Completed) AT (Completed) NL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002034-36 | Sponsor Protocol Number: V937-011 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metas... | |||||||||||||
Medical condition: Advanced/metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
